文献速递胸部腹部MR

影像组学检测NSCLC肝转移EGFR突变

Radiomics for Detection of the EGFR Mutation in Liver Metastatic NSCLC.
PubMed 文献 · Acad Radiol · 2022-07-27

本研究纳入130例病理确诊的原发性NSCLC肝转移患者,提取原发灶与转移灶瘤内及瘤周MRI影像组学特征,用LASSO构建预测EGFR突变状态的组学标签。联合原发灶与转移灶的RS-Combine在训练集和测试集AUC分别为0.908和0.884,优于单一病灶标签。基于肝转移的影像组学可用于检测EGFR突变,多器官联合标签可能辅助个体化治疗决策。

要点

  • 联合原发灶与肝转移灶的影像组学标签预测EGFR突变效能最高,测试集AUC 0.884。
  • 单一肝转移灶影像组学标签测试集AUC 0.791,原发灶标签为0.760。
  • 训练集中吸烟状态在EGFR突变型与野生型组间差异有统计学意义(p < 0.05)。

核心结论

  • 基于肝转移灶的MRI影像组学可用于检测NSCLC患者的EGFR突变状态。
  • 联合原发灶与转移灶的多器官影像组学标签预测效能最高,可能有助于指导转移性NSCLC患者的个体化治疗策略。

研究设计与样本

  • 使用pyradiomics提取原发灶和转移灶瘤内及瘤周区域的MRI影像组学特征。
  • 采用LASSO回归筛选最具预测价值的特征并构建预测EGFR突变状态的影像组学标签(RSs)。
  • 以ROC曲线分析评估所构建RSs的预测能力,并分为训练集与测试集进行验证。

诊断标准与关键数值

  • 训练集AUC:RS-Primary 0.826,RS-Metastasis 0.821,RS-Combine 0.908。
  • 测试集AUC:RS-Primary 0.760,RS-Metastasis 0.791,RS-Combine 0.884。
  • 训练集中吸烟状态在EGFR突变组与野生型组间差异有统计学意义(p < 0.05)。

临床应用与阅片要点

  • 阅片时可同时关注原发灶与肝转移灶的影像组学特征,联合模型预测EGFR突变效能优于单一病灶。
  • 影像组学标签可作为无创预测EGFR突变状态的辅助工具,但需结合吸烟状态等临床信息综合判断。

局限性

  • 单中心回顾性研究,样本量有限(130例),结论需外部多中心验证。
  • 研究仅基于MRI影像组学,未报告具体的MRI设备、序列参数及外部验证结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: The research aims to investigate whether MRI radiomics on hepatic metastasis from primary nonsmall cell lung cancer (NSCLC) can be used to differentiate patients with epidermal growth factor receptor (EGFR) mutations from those with EGFR wild-type, and develop a prediction model based on combination of primary tumor and the metastasis.

MATERIALS AND METHODS: A total of 130 patients were enrolled between Aug. 2017 and Dec. 2021, all pathologically confirmed harboring hepatic metastasis from primary NSCLC. The pyradiomics was used to extract radiomics features from intra- and peritumoral areas of both primary tumor and metastasis. The least absolute shrinkage and selection operator (LASSO) regression was applied to identify most predictive features and to develop radiomics signatures (RSs) for prediction of the EGFR mutation status. The receiver operating characteristic (ROC) curve analysis was performed to assess the prediction capability of the developed RSs.

RESULTS: A RS-Primary and a RS-Metastasis were derived from the primary tumor and metastasis, respectively. The RS-Combine by combination of the primary tumor and metastasis achieved the highest prediction performance in the training (AUCs, RS-Primary vs. RS-Metastasis vs. RS-Combine, 0.826 vs. 0.821 vs. 0.908) and testing (AUCs, RS-Primary vs. RS-Metastasis vs. RS-Combine, 0.760 vs. 0.791 vs. 0.884) set. The smoking status showed significant difference between EGFR mutant and wild-type groups (p < 0.05) in the training set.

CONCLUSION: The study indicates that hepatic metastasis-based radiomics can be used to detect the EGFR mutation. The developed multiorgan combined radiomics signature may be helpful to guide individual treatment strategies for patients with metastatic NSCLC.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Hou, Fan, Wang, et al. Radiomics for Detection of the EGFR Mutation in Liver Metastatic NSCLC. Acad Radiol. 2022. PMID: 35907759. doi:10.1016/j.acra.2022.06.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。